GERN - ジェロン （Geron Corporation）

Geron is executing in the clinic with success in IMerge, and other studies are set to read out in late 2023, 2024, and beyond. Find out why GERN stock is a Buy.

Geron (GERN) said that its planned New Drug Application for imetelstat for lower risk myelodysplastic syndromes is on track for submission in June. Read more here.

GERN earnings call for the period ending March 31, 2023.

Geron Corporation (NASDAQ:NASDAQ:GERN) Q1 2023 Results Conference Call May 11, 2023 10:30 AM ETCompany ParticipantsAron Feingold - VP, IR and Corporate CommunicationsDr.

Longer follow-up data for 1-year transfusion independence (TI) in IMerge Phase 3, which demonstrated statistically significant and clinically meaningful continuous, durable efficacy Strong correla…

In last trading session, Geron Corporation (NASDAQ:GERN) saw 3.3 million shares changing hands with its beta currently measuring 0.69. Company’s recent per share price level of $3.37 trading at -$0.03 or -0.88% at ring of the bell on the day assigns it a market valuation of $1.24B. That closing price of GERN’s stock is at … Geron Corporation Shares Rise 70.62% From The Lows – But Will They Continue? Read More »

The overall stock market may be demonstrating resilience, but as uncertainty continues to run high, stocks have only made a modest, partial recovery. However, this works to your advantage, as many stocks remain at low prices, including the best stocks to buy for less than $25 per share. Although investors are starting to wager on a 2023 pivot on interest rates by the Federal Reserve , inflation remains at multi-decade highs. The Fed could still decide to keep raising rates until inflation starts to ease. With this, there may be a round or two of additional volatility before the bull market returns. Yet if you focus on high-quality lower-priced stocks, this isn’t a major concern. These names can handle additional volatility. Some of these could perform strongly with secular growth catalysts even if the overall stock market stays in a slump throughout the year. So, what are the best stocks to buy for less than $25 per share? Consider these seven. Each one earns an A rating in Portfolio Grader.

There are two main reasons why moving averages are useful in forex trading: moving averages help traders define trend recognize changes in trend. Now well have a look on, SMA50 … The post Charming stocks: Geron Corporation (NASDAQ:GERN 3.91%), Walmart Inc. (NYSE:WMT 1.23%) appeared first on Stocks Equity .

Geron Corporation (GERN) announced new additions to its senior commercial leadership on Wednesday ahead of the planned launch of blood cancer therapy imetelstat. Read the full story here.

Primary endpoint of 8-week transfusion independence met in Geron Corporation''s phase 3 IMerge study. Read more to see why I''m bullish on GERN.

Geron will topline its IMerge trial by early January, a pivotal event in the life of the company. Read more to see my recommendation on GERN stock.

Geron Corporation (NASDAQ:GERN) concluded the trading at $2.20 on Wednesday, November 23 with a fall of -2.65% from its closing price on previous day. Taking a look at stock we notice that its last check on previous day was $2.26 and 5Y monthly beta was reading 0.76 with its price kept floating in the range … Geron Corporation (GERN) Outlook: Revisiting The Past For Future Insights Read More »

Geron Corporation (NASDAQ:GERN) has a beta value of 0.78 and has seen 2.95 million shares traded in the last trading session. The company, currently valued at $816.05M, closed the last trade at $2.15 per share which meant it lost -$0.11 on the day or -4.87% during that session. The GERN stock price is -42.33% off … Geron Corporation (GERN) Suffers From Weak Fundamental Momentum Read More »

Geron Corporation (GERN)’s stock has witnessed a price hike of 5.82% from the previous close with its current price standing at $2.22. Its current price is -27.38% under its 52-week high of $3.06 and 124.49% more than its 52-week low of $0.99. Based on the past 30-day period, the stock price is -10.51% below the […]

FOSTER CITY, Calif.--(BUSINESS WIRE)--Geron Corporation (Nasdaq: GERN), a late-stage biopharmaceutical company focused on the development and commercialization of treatments for hematologic malignancies, today announced that John A. Scarlett, M.D., Geron’s Chairman and Chief Executive Officer, is scheduled to participate in a fireside chat in person at the Stifel 2022 Healthcare Conference in New York City on Tuesday, November 15, 2022 at 10:55 a.m. ET. A webcast of the presentation will be ava